Phase 1/2Status unknown
A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer
- Sponsor
- Panacela Labs LLC (Industry)
- Enrollment
- 24 planned
- Conditions
- Prostate Cancer
- Interventions
- Mobilan (M-VM3); Placebo
- Ages
- adults, older adults
- Registry
- NCT02844699
Full record on ClinicalTrials.gov
From the registry
A Phase Ib2, multicenter, randomized, double-blind, placebo-controlled safety and efficacy study evaluating different regimens of the immunotherapeutic drug, Mobilan (M-VM3), in patients with prostate cancer.
Primary outcomes
- Frequency and intensity of adverse events (according to CTCAE v 4.03 classification)
- Counting of CD4+ and CD8+ cells in prostate biopsy and surgery samples
History
Primary completion
Last registry update
Registered
Started